BIO-RAD LABORATORIES, INC. acquired Dropworks, Inc. for $125.5 million total consideration, a transaction completed in October 2021, structured as all cash.
Dropworks, Inc. operates in Life Science. Dropworks is a development-stage company focused on developing a digital PCR product.
The strategic rationale for the transaction was to address additional opportunities in the PCR market.
Early-stage digital PCR technology expanding Bio-Rad's PCR roadmap. Complements Life Science product offerings and addresses additional PCR-market opportunities. Life Science segment Per FY2025 10-K: in December 2025 Bio-Rad impaired the IPR&D asset associated with the 2021 Dropworks acquisition for $81.7 million, citing technology-completion delays and a revised revenue forecast.
Dropworks is a development stage company focused on developing a digital PCR product. The strategic rationale for the transaction was to address additional opportunities in the PCR market.Bio-Rad Laboratories FY2021 10-K, Acquisition note
Advisory firms were not disclosed for this transaction.